Role of Local Radiation Therapy in Cancer Immunotherapy.
暂无分享,去创建一个
[1] R. Weichselbaum,et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells , 2007, The Journal of experimental medicine.
[2] R. Tibshirani,et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L. Milas,et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] S. Rosenberg,et al. Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.
[5] N. Kawashima,et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] K. Schäkel,et al. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. , 2013, Cancer cell.
[7] C. N. Coleman,et al. Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy , 2003, The Journal of Immunology.
[8] B. Loo,et al. Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response , 2014, Clinical Cancer Research.
[9] R. Weichselbaum,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.
[10] K. Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.
[11] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[12] Su-Chen Huang,et al. Reciprocal Complementation of the Tumoricidal Effects of Radiation and Natural Killer Cells , 2013, PloS one.
[13] N. Kawashima,et al. Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells1 , 2008, The Journal of Immunology.
[14] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[15] S. Demaria,et al. An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.
[16] S. Demaria,et al. Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes , 2014, Journal of Immunotherapy for Cancer.
[17] S. Demaria,et al. Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.
[18] G. Plitas,et al. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy , 2013, The Journal of experimental medicine.
[19] S. Hori,et al. Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras , 2007, Proceedings of the National Academy of Sciences.
[20] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[21] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.
[22] H. Kohrt,et al. Current clinical trials testing combinations of immunotherapy and radiation. , 2015, Seminars in radiation oncology.
[23] S. Demaria,et al. The convergence of radiation and immunogenic cell death signaling pathways , 2012, Front. Oncol..
[24] N. Kawashima,et al. The Combination of Ionizing Radiation and Peripheral Vaccination Produces Long-term Survival of Mice Bearing Established Invasive GL261 Gliomas , 2006, Clinical Cancer Research.
[25] S. Demaria,et al. Radiation as an immunological adjuvant: current evidence on dose and fractionation , 2012, Front. Oncol..
[26] V. Sondak,et al. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. , 2012, International journal of radiation oncology, biology, physics.
[27] N. Kawashima,et al. Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer , 2012, Clinical Cancer Research.
[28] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[29] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[30] P. Zatloukal,et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Tschopp,et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.
[32] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[33] B. Vikram,et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. , 1999, Cancer research.
[34] S. Demaria,et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death , 2014, Oncoimmunology.
[35] R. Weichselbaum,et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.
[36] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[37] S. Demaria,et al. Up-regulation of the Pro-inflammatory Chemokine CXCL16 is a Common Response of Tumor Cells to Ionizing Radiation , 2010, Radiation research.
[38] S. Adams. Toll-like receptor agonists in cancer therapy. , 2009, Immunotherapy.
[39] S. Demaria,et al. Radiation therapy to convert the tumor into an in situ vaccine. , 2012, International journal of radiation oncology, biology, physics.
[40] Laurence Zitvogel,et al. Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.
[41] S. Swetter,et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. , 2012, Translational oncology.
[42] E. Tartour,et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.
[43] R. Schreiber,et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.
[44] N. Kawashima,et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. , 2012, The Journal of clinical investigation.
[45] G. Coukos,et al. Targeting the tumor vasculature to enhance T cell activity , 2015, Current opinion in immunology.
[46] Ira Mellman,et al. Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.
[47] N. Kawashima,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.
[48] P. Coulie,et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.
[49] P. Ascierto,et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy , 2014, Oncoimmunology.
[50] S. Demaria,et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.
[51] Fumito Ito,et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. , 2003, Cancer research.
[52] N. Kawashima,et al. Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.
[53] L. Zitvogel,et al. Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.
[54] Ying Wang,et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.
[55] Stephen Mok,et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.
[56] C. Chiang,et al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. , 2007, International journal of radiation oncology, biology, physics.
[57] Robert C. Rose,et al. Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.
[58] W. McBride,et al. Regulatory T Cells in Radiotherapeutic Responses , 2012, Front. Oncol..
[59] C. N. Coleman,et al. Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer , 2005, Clinical Cancer Research.
[60] T. Hellevik,et al. Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation , 2014, Front. Oncol..
[61] D. Fearon,et al. T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.
[62] S. Demaria,et al. Systemic effects of local radiotherapy. , 2009, The Lancet. Oncology.
[63] I. Stratford,et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.
[64] John Wong,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.
[65] S. Gerber,et al. Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.
[66] R. Derynck,et al. Transforming growth factor-beta activation in irradiated murine mammary gland. , 1994, The Journal of clinical investigation.
[67] A. Debucquoy,et al. T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy , 2008, Clinical Cancer Research.
[68] Gwendoline Gros,et al. Cutting Edge: Hypoxia-Induced Nanog Favors the Intratumoral Infiltration of Regulatory T Cells and Macrophages via Direct Regulation of TGF-β1 , 2013, The Journal of Immunology.
[69] A. Tsao. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study , 2012 .
[70] H. Schreiber,et al. Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.
[71] Susanta Hui,et al. Radiation-Induced Vascular Damage in Tumors: Implications of Vascular Damage in Ablative Hypofractionated Radiotherapy (SBRT and SRS) , 2012, Radiation research.
[72] O. Lund,et al. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage , 2005, Immunogenetics.
[73] J. Zavadil,et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. , 2015, Cancer research.
[74] K. Murphy,et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.
[75] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.